Veracyte, Inc. reported $542M of revenue over the trailing twelve months, +17% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $542M (to Q1 2026). Net Income: $88M, trailing twelve months to Q1 2026. Free Cash Flow: $155M, trailing twelve months to Q1 2026. Op Margin: 14%, trailing twelve months to Q1 2026.

VCYTVeracyte, Inc.

HealthcareUSD

$44.28

$27.3752 weeks$59.55

VCYT as reported

Veracyte, Inc. reported $542M of revenue over the trailing twelve months, +17% on the year before. 11 reported series are charted on this page, each one as filed.

$542M

Revenue, trailing twelve months · to Q1 2026 · +17% against the twelve months before

Net Income: $88M
Net Income · +166% year on year · trailing twelve months to Q1 2026
Free Cash Flow: $155M
Free Cash Flow · +98% year on year · trailing twelve months to Q1 2026
Op Margin: 14%
Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for VCYT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$542M	+17%	Q1 2026
Net Income	$88M	+166%	Q1 2026
EPS	$1.08	+163%	Q1 2026
Gross Margin	71%	n/a	Q1 2026
Op Margin	14%	n/a	Q1 2026
Net Margin	16%	n/a	Q1 2026
ROE	4.0%	n/a	Q1 2026
ROA	3.8%	n/a	Q1 2026
ROIC	−4.3%	n/a	Q4 2022 · 13 quarters behind
Free Cash Flow	$155M	+98%	Q1 2026
P/E	41.0	n/a	today